CEO Rick Pauls was paid $2,727,350 in fiscal year 2025, ↑ up 75.8% from fiscal year 2024, the 70th percentile of its disclosed peer group (SEC filing 0001437749-26-010879 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,727,350 ↑ Rick Pauls total, FY2025 | 70th CEO pay percentile vs peers | — CEO-to-median pay ratio | 97.34% Say-on-pay support, latest vote |
You have just read DiaMedica Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper DMAC reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
DMAC's next annual pay disclosure, estimated April 1, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rick Pauls | $645,000 | $0 | $0 | $1,652,400 | $412,500 | $0 | $17,450 | $2,727,350 |
| President and Chief Executive Officer | ||||||||
| Julie Krop | 198,980 | 0 | 0 | 1,421,100 | 79,592 | 0 | 7,891 | 1,707,563 |
| Chief Medical Officer | ||||||||
| Scott Kellen | 408,500 | 0 | 0 | 619,650 | 183,920 | 0 | 17,450 | 1,229,520 |
| Chief Financial Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Rick Pauls | $2,727,350 | $1,550,985 | $1,215,161 | ↑ +1,176,365 |
| Julie Krop | 1,707,563 | — | — | — |
| Scott Kellen | 1,229,520 | 813,955 | 632,215 | ↑ +415,565 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Julie Krop | Chief Medical Officer | $1,707,563 |
| Rick Pauls | CEO | $2,727,350 |
| Scott Kellen | CFO | $1,229,520 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Charles Semba, M.D | Independent Director | $145,972 |
| Daniel O’Connor | Independent Director | $358,273 |
| James Parsons | Chair of the Board | $199,898 |
| Michael Giuffre, M.D | Independent Director | $148,418 |
| Richard Kuntz, M.D | Independent Director | $143,261 |
| Tanya Lewis | Independent Director | $141,574 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Rick Pauls | Option | 154,876 | 2.45 | — |
| Rick Pauls | Option | 113,125 | 2.73 | — |
| Rick Pauls | Option | 112,500 | 2.9 | — |
| Scott Kellen | Option | 52,500 | 2.45 | — |
| Scott Kellen | Option | 41,875 | 2.73 | — |
| Scott Kellen | Option | 48,750 | 2.9 | — |
DiaMedica's executive compensation policies, plans and programs seek to enhance financial performance and shareholder value by aligning the financial interests of executives with those of shareholders and emphasizing pay-for-performance. The company emphasizes that a significant portion of executive compensation is at risk and paid in equity, while avoiding guaranteed salary increases, bonuses, or perquisites.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 9,928,381 | 271,093 | 149,163 | 97.34% | Passed |
| 2025 | 2025-05-15 | 6,536,608 | 398,959 | 11,788 | 94.25% | Passed |
| 2024 | 2024-05-22 | 13,178,728 | 564,691 | 254,912 | 95.89% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-20 | 97.34%a |
| 2025 | 2025-05-15 | 94.25%b |
| 2024 | 2024-05-22 | 95.89%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel O’ConnorIndependent · Nominating and Corporate Governance · Audit · Compensation (Chair) | $56,104 | $0 | $302,169 | — | $0 | $358,273 |
| James ParsonsIndependent · Board Chair · Audit Committee (Chair) | 85,000 | 2,703 | 112,195 | — | 0 | 199,898 |
| Michael Giuffre, M.DIndependent · Nominating and Corporate Governance (Chair) · Scientific & Clinical Research | 58,000 | 1,844 | 88,574 | — | 0 | 148,418 |
| Charles Semba, M.DIndependent · Audit · Compensation · Scientific and Clinical Research | 56,500 | 898 | 88,574 | — | 0 | 145,972 |
| Richard Kuntz, M.DIndependent · Compensation · Scientific and Clinical Research (Chair) | 53,000 | 1,687 | 88,574 | — | 0 | 143,261 |
| Tanya LewisIndependent · Compensation Committee · Nominating and Corporate Governance Committee · Scientific and Clinical Research Committee | 53,000 | 0 | 88,574 | — | 0 | 141,574 |
| Rick PaulsEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $361,604 |
| Equity awards (grant-date value) | $7,132 |
| All other compensation | $0 |
| Total cost of the board | $368,736 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies DiaMedica Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including DiaMedica Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Mineralys Therapeutics, Inc. | 2025 | Jon Congleton | $636,500 | $0 | $4,435,626 | $472,601 | $5,544,727 |
| 2 | Anavex Life Sciences Corp. | 2025 | Christopher Missling | 723,485 | 0 | 3,083,000 | 0 | 3,959,085 |
| 3 | Fulcrum Therapeutics, Inc. | 2025 | Alex Sapir | 650,000 | 0 | 2,052,132 | 411,200 | 3,251,490 |
| 4 | DiaMedica Therapeutics | 2025 | Rick Pauls | 645,000 | 0 | 1,652,400 | 412,500 | 2,727,350 |
| 5 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 6 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 7 | Alto Neuroscience, Inc. | 2025 | Amit Etkin | 650,671 | 0 | 934,186 | 358,072 | 2,188,487 |
| 8 | Lineage Cell Therapeutics, Inc. | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 9 | Acumen Pharmaceuticals, Inc. | 2025 | Daniel O'Connell | 646,354 | 412,482 | 478,338 | 305,725 | 1,863,567 |
| 10 | Galectin Therapeutics Inc. | 2025 | Joel Lewis | 624,000 | 182,763 | — | — | 1,174,782 |
| 11 | Ovid Therapeutics Inc | 2025 | Margaret Alexander | 515,000 | 24,806 | 118,466 | 350,000 | 1,022,272 |
| — | Tourmaline Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Applied Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | PepGen Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Vigil Neuroscience, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Annovis Bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | MediciNova, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| DiaMedica Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Acumen Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Alto Neuroscience, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Anavex Life Sciences Corp. | not disclosed | Option 100 | not disclosed | not disclosed |
| Annovis Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Applied Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Fulcrum Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Galectin Therapeutics Inc. | 100% | not disclosed | not disclosed | Barney & Barney LLC |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Lineage Cell Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Anderson |
| MediciNova, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Mineralys Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Ovid Therapeutics Inc | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLP |
| PepGen Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Tourmaline Bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Vigil Neuroscience, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Rick Pauls | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Summary Compensation Table” · page 46. As printed: 2,727,350. View filing ↗ |
| 2 | Section 01, Julie Krop | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Summary Compensation Table” · page 46. As printed: 1,707,563. View filing ↗ |
| 3 | Section 01, Scott Kellen | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Summary Compensation Table” · page 46. As printed: 1,229,520. View filing ↗ |
| 4 | Section 08, Daniel O’Connor | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 358,273. View filing ↗ |
| 5 | Section 08, James Parsons | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 199,898. View filing ↗ |
| 6 | Section 08, Michael Giuffre, M.D | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 148,418. View filing ↗ |
| 7 | Section 08, Charles Semba, M.D | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 145,972. View filing ↗ |
| 8 | Section 08, Richard Kuntz, M.D | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 143,261. View filing ↗ |
| 9 | Section 08, Tanya Lewis | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 141,574. View filing ↗ |
| 10 | Section 08, Rick Pauls | DEF 14A | 2026-04-01 | 0001437749-26-010879 | Section “Director Compensation”. As printed: 0. View filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-05-21 | 0001437749-26-018106 | Item 5.07 · say-on-pay result. As reported: 97.34% (votes for as printed: 9,928,381). View filing ↗ |
| 12 | Section 06, 2025 vote | Form 8-K | 2025-05-15 | 0001437749-25-017239 | Item 5.07 · say-on-pay result. As reported: 94.25% (votes for as printed: 6,536,608). View filing ↗ |
| 13 | Section 06, 2024 vote | Form 8-K | 2024-05-23 | 0001437749-24-018140 | Item 5.07 · say-on-pay result. As reported: 95.89% (votes for as printed: 13,178,728). View filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer. |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 361,604 + equity 7,132 + all other 0 = 368,736, summed across the director compensation table rows. |
| 16 | Mineralys Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001933414-26-000069 | CEO total compensation as printed in Mineralys Therapeutics, Inc.'s own proxy. As printed: 5,544,727. View filing ↗ |
| 17 | Anavex Life Sciences Corp., Section 10b CEO total | DEF 14A | 2026-08-11 | 0001731122-26-001038 | CEO total compensation as printed in Anavex Life Sciences Corp.'s own proxy. As printed: 3,959,085. View filing ↗ |
| 18 | Fulcrum Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197196 | CEO total compensation as printed in Fulcrum Therapeutics, Inc.'s own proxy. As printed: 3,251,490. View filing ↗ |
| 19 | DiaMedica Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-01 | 0001437749-26-010879 | CEO total compensation as printed in DiaMedica Therapeutics's own proxy. As printed: 2,727,350. View filing ↗ |
| 20 | Inozyme Pharma, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060198 | CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. View filing ↗ |
| 21 | Gossamer Bio, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001728117-26-000027 | CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗ |
| 22 | Alto Neuroscience, Inc., Section 10b CEO total | DEF 14A | 2026-03-26 | 0001104659-26-035180 | CEO total compensation as printed in Alto Neuroscience, Inc.'s own proxy. As printed: 2,188,487. View filing ↗ |
| 23 | Lineage Cell Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191556 | CEO total compensation as printed in Lineage Cell Therapeutics, Inc.'s own proxy. As printed: 2,111,170. View filing ↗ |
| 24 | Acumen Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026870 | CEO total compensation as printed in Acumen Pharmaceuticals, Inc.'s own proxy. As printed: 1,863,567. View filing ↗ |
| 25 | Galectin Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-10-13 | 0001140361-26-039379 | CEO total compensation as printed in Galectin Therapeutics Inc.'s own proxy. As printed: 1,174,782. View filing ↗ |
| 26 | Ovid Therapeutics Inc, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027621 | CEO total compensation as printed in Ovid Therapeutics Inc's own proxy. As printed: 1,022,272. View filing ↗ |
| 27 | Section 10a, Gossamer Bio, Inc. reciprocity | DEF 14A | — | 0001728117-26-000027 | Gossamer Bio, Inc.'s most recent proxy was read; its disclosed peer group does not include DiaMedica Therapeutics. View filing ↗ |
| 28 | Section 10a, Lineage Cell Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191556 | Lineage Cell Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include DiaMedica Therapeutics. View filing ↗ |